tsc-204-a0201
tsc-204-a0201: sourced relationships with 1 company · 1 clinical trial tracked.
tsc-204-a0201 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could tsc-204-a0201 → TCRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| TScan Therapeutics, Inc. (TCRX) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Primary endpoint: Evaluate the safety of monotherapy and T- Plex combination TCR-Ts
Frequently asked questions
Which companies have sourced relationships with tsc-204-a0201?
tsc-204-a0201 has dated SEC/FDA relationship records for TScan Therapeutics, Inc..
How many clinical trials involve tsc-204-a0201?
BioSniper tracks 1 clinical trial involving tsc-204-a0201.